Trial Profile
An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Brain cancer
- Focus Pharmacokinetics
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 16 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 08 Mar 2021 Planned End Date changed from 1 Sep 2019 to 31 Dec 2021.